Besides, the presence of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is predictive of response to temozolomide-based chemotherapy in patients with IDH-wild-type glioma (Wick et al., 2012). This evidence concerns the gene MGMT and central nervous system cancer.